Amarchand, AZB, Wadia Ghandy, Tatva and Simpson Thacher act on KKR $200 million investment in Gland Pharma

US Private Equity fund, KKR is investing $200 million (Rs. 1,300 crore) in Hyderabad based pharmaceuticals manufacturer, Gland Pharma Limited, making it one of the largest private equity investments in the pharmaceuticals sector in India..The investment is proposed to be made through a combination of a preferential allotment by Gland Pharma and a simultaneous purchase by KKR of the entire stake held by EILSF Co-Invest I LLC, giving it an exit..Amarchand Mangaldas advised KKR with a team led by Mumbai based Managing Partner Cyril Shroff along with Corporate Partner Reeba Chacko..Amarchand’s Bangalore-based Real Estate & Litigation Partner, Namrata Kolar advised on litigation and real estate issues while Competition Law Partner Nisha Kaur Uberoi is advising on the competition law aspects of this deal..Simpson Thacher & Bartlett LLP acted as International legal counsel with a team led by Partner Mark Pflug..AZB & Partners advised Gland Pharma Limited with a team led by Partner Essaji Vahanvati..Wadia Ghandy advised EILSF Co-Invest I LLC with a team led by Partner Ankit Majmudar while Tatva Legal advised the existing investors of Gland Pharma with a team led by Partner Shailendra Komatreddy..Earlier this year, KKR had acquired a controlling stake in specialised tyre maker Alliance Tire Group from Warburg Pincus for $630 million where AZB & Partners had advised KKR and Amarchand Mangaldas had advised Warburg Pincus and Alliance.